Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €28.11 EUR
Change Today -2.65 / -8.60%
Volume 0.0
ZA7 On Other Exchanges
As of 2:14 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

175 Portland Street

4th Floor

Boston, MA 02114

United States

Phone: 617-622-4003


Zafgen, Inc., a biopharmaceutical company, focuses on improving the health and well-being of patients affected by obesity. Beloranib Beloranib, the company’s main product candidate, is a first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. Beloranib is a potent inhibitor of MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism. Strategy The company’s objective is to be a leader in the discovery, development and commercialization of novel therapies to significantly improve the health and well-being of patients affected by obesity. Main elements of the company’s strategy include the following: advancing the clinical development of beloranib in subpopulations of obese patients, including those with rare conditions, where obesity is a co-morbidity of an underlying condition; advancing the clinical development of MetAP2 inhibitors for the treatment of severely obese patients in the general population, including those who are candidates for bariatric surgery; leveraging the knowledge of experienced team of drug developers that have deep expertise in the field of obesity, the function of MetAP2 inhibitors and metabolic diseases; maintaining flexibility in commercializing and maximizing the value of development programs; and developing other potential product candidates. Intellectual Property The company’s owned and licensed patents and patent applications relate to beloranib compositions of matter, formulations, polymorphs, methods of treating obesity using dosing regimens of beloranib and methods of treating hypothalamic obesity. The issued U.S. and European patents generally directed to beloranib compositions of matter are exclusively licensed and would each expire in 2019. The company owns an issued U.S. patent relating to beloranib polymorph compositions of matter that would expire in 2031 and an issued U.S. patent to methods of treating obesity that would expire in 2029. As of February 28, 2014, the company owned two issued U.S. patents, eight pending U.S. patent applications and foreign counterpart applications, and one Patent Cooperation Treaty (PCT) application, all of which relate to beloranib. As of February 28, 2014, the company owned seven pending U.S. patent applications with pending foreign counterpart applications and five PCT patent applications, all of which relate to MetAP2 inhibitor program. Of these, one pending U.S. patent application with pending foreign counterpart patent applications and one PCT patent application relate to early-stage product candidate ZGN-839. As of February 28, 2014, the company owned two pending U.S patent applications with pending foreign counterpart patent applications, one pending PCT patent application and two U.S. provisional patent applications that relate to second-generation MetAP2 inhibitor program. The company owns various U.S. federal trademark registrations and applications and unregistered trademarks, including the following trademarks: ZAFGEN and corporate logo. History Zafgen, Inc. was founded in 2005. The company was incorporated under the laws of the state of Delaware in 2005.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZA7:GR €28.11 EUR -2.65

ZA7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZA7.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZA7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at